Secondary prevention of HMG-CoA reductase inhibitor against stroke

INTERVENTION: Patients will be randomized into the group receiving pravastatin or that having no statin. Intervention consists of pravastain treatment (10mg/day), that will start within 1 month of entry and continue until the end of study or the endpoints. Non‐administration group of pravastatin (control group) CONDITION: Ischemic stroke PRIMARY OUTCOME: cerebrovascular events SECONDARY OUTCOME: Events of ischemic stroke (subtype analysis according to the TOAST classification) or hemorrhagic stroke, cardiovascular events including myocardial infarction, all the cerebrovascular and cardiovascular events, death of stroke, death of vascular events, death of all causes, admission to the hospital, activity of daily life, modified Rankin score, dementia and cognitive impairment, death of all causes. INCLUSION CRITERIA: 1) Ischemic stroke except for cardiogenic embolism, from 1 month to 3 years after onset 2) 45‐80 years old 3) Patients diagnosed as hyperlipidemia 4) No taking of HMG‐CoA reductase inhibitor, any statin, within previous 30 days. 5) The total cholesterol level of 180‐240mg/dl without the prescription of statin within previous 30 days. 6)Able to visit outpatient department 7) Informed consent on the form filled out by the patient.